<SEC-DOCUMENT>0001140361-24-008303.txt : 20240322
<SEC-HEADER>0001140361-24-008303.hdr.sgml : 20240322
<ACCEPTANCE-DATETIME>20240216113925
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001140361-24-008303
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20240216

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BRISTOL MYERS SQUIBB CO
		CENTRAL INDEX KEY:			0000014272
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				220790350
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		ROUTE 206 AND PROVINCE LINE ROAD
		CITY:			PRINCETON
		STATE:			NJ
		ZIP:			08543
		BUSINESS PHONE:		6092524621

	MAIL ADDRESS:	
		STREET 1:		ROUTE 206 AND PROVINCE LINE ROAD
		CITY:			PRINCETON
		STATE:			NJ
		ZIP:			08543

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BRISTOL MYERS CO
		DATE OF NAME CHANGE:	19891012
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Finanicial Soultions, Inc.
         Document created using Broadridge PROfile 23.12.1.5186
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <div><img src="ny20021323x3_image01.jpg"></div>
    <div><br>
    </div>
    <div style="text-align: justify;">February 16, 2024</div>
    <div><br>
    </div>
    <div style="text-align: justify;">VIA EDGAR</div>
    <div><br>
    </div>
    <div style="text-align: justify;">U.S. Securities and Exchange Commission</div>
    <div style="text-align: justify;">Division of Corporation Finance</div>
    <div style="text-align: justify;">100 F Street, NE</div>
    <div style="text-align: justify;">Washington, DC 20549</div>
    <div><br>
    </div>
    <div style="text-align: justify;">Attention: Laura McKenzie and Christina Chalk, Division of Corporation Finance, Office of Mergers &amp; Acquisitions</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zdf3c8b1999b9483b9d33994aa7daa5f6" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 3%; vertical-align: top;">
            <div style="text-align: justify;">Re:</div>
          </td>
          <td style="width: 97%; vertical-align: top;">
            <div style="text-align: justify;">Bristol-Myers Squibb Company</div>
            <div style="text-align: justify;">RayzeBio, Inc.</div>
            <div style="text-align: justify;">Schedule TO-T filed January 25, 2024</div>
            <div style="text-align: justify;">File No. 005-94159</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: justify;">Dear Ms. McKenzie and Ms. Chalk:</div>
    <div><br>
    </div>
    <div style="text-align: justify;">This letter responds to the comment letter dated February 14, 2024, from the staff (the &#8220;Staff&#8221;) of the U.S. Securities and Exchange Commission (the &#8220;Commission&#8221;) with respect to the above-referenced Tender Offer
      Statement on Schedule TO (the &#8220;Schedule TO&#8221;) of Bristol-Myers Squibb Company (&#8220;Parent&#8221;) and Rudolph Merger Sub Inc., a wholly owned subsidiary of Parent (&#8220;Purchaser&#8221;). Concurrently with our submission of this letter, Parent and Purchaser are filing
      an amendment to the Schedule TO, setting forth the changes described herein (the &#8220;TO Amendment&#8221;). Capitalized terms used but not defined herein have the meanings ascribed to them in the Schedule TO.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">For the convenience of the Staff, Parent and Purchaser have reproduced in bold the text of the Staff&#8217;s comments, with their response immediately following each comment.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-weight: bold;"><u>Schedule TO-T filed January 25, 2024</u></div>
    <div><br>
    </div>
    <div style="text-align: justify; font-weight: bold;"><u>Source and Amount of Funds, page 24</u></div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zadbfd8e1a34748ce8987d743fe9e0751" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 5.45pt;"><br>
          </td>
          <td style="width: 35.35pt; vertical-align: top; font-weight: bold;">1.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">Disclose the existence of any alternative financing plans or arrangements in the event you do not have the necessary funds to pay the offer consideration and related fees and expenses. If there are none, so
              state. Refer to Item 1007(b) of Regulation M-A.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 40.8pt;"><u>Response</u>: Parent and Purchaser respectfully acknowledge the Staff&#8217;s comment and advise the Staff that the TO Amendment sets forth revised disclosure on pages 2 and 24 of the Offer to
      Purchase in response to the Staff&#8217;s comment.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-weight: bold;"><u>Conditions to the Offer, page 45</u></div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z02c098ad23a443cb9081298b84a25e8d" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 5.45pt;"><br>
          </td>
          <td style="width: 35.35pt; vertical-align: top; font-weight: bold;">2.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">We note your disclosure in the first paragraph on page 47 that certain conditions &#8220;may be waived by Parent or Purchaser in whole or in part at any time and from time to time and in the sole discretion of Parent
              or Purchaser.&#8221; If an event occurs that implicates an offer condition, an offeror must promptly inform security holders whether it will waive the condition and continue with the Offer, or terminate the Offer based on that condition. In this
              respect, reserving the right to waive a condition &#8220;at any time and from time to time&#8221; is inconsistent with your obligation to inform security holders promptly if events occur that &#8220;trigger&#8221; an offer condition. Please revise here and later in
              the same paragraph, where you state that &#8220;failure by Parent, Purchaser or any other affiliate of Parent at any time to exercise any of the foregoing rights will not be deemed a waiver of any such right . . . and each such right will be deemed
              an ongoing right that may be asserted at any time and from time to time.&#8221;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 40.8pt;"><u>Response</u>: Parent and Purchaser respectfully acknowledge the Staff&#8217;s comment and confirm their intention to comply with applicable Commission rules and regulations. To that end, Parent and
      Purchaser hereby confirm that upon their discovery of any facts or circumstances that would give rise to an offer condition not being satisfied, they will undertake to promptly inform RayzeBio stockholders as to whether they will assert the condition
      and terminate the Offer, or waive it and continue with the Offer. Parent and Purchaser also advise the Staff that the TO Amendment sets forth revised disclosure on page 47 of the Offer to Purchase in response to the Staff&#8217;s comment.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zdeb997969356418abd24fe42b9b68725" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 5.45pt;"><br>
          </td>
          <td style="width: 35.35pt; vertical-align: top; font-weight: bold;">3.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">Refer to the following statement on page 47 in this section: &#8220;The foregoing conditions are in addition to, and not a limitation of, the rights of Parent and Purchaser to extend, terminate or modify the Offer
              pursuant to the terms of the Merger Agreement.&#8221; This statement suggests there are additional conditions that will allow Parent and Purchaser to terminate the Offer. Please revise to describe all Offer conditions here, or revise.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 40.8pt;"><u>Response</u>: Parent and Purchaser respectfully acknowledge the Staff&#8217;s comment and confirm to the Staff that all Offer conditions have been disclosed in the Offer to Purchase and the Schedule
      TO. In addition, the TO Amendment sets forth revised disclosure on page 47 of the Offer to Purchase in response to the Staff&#8217;s comment.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-weight: bold;"><u>Miscellaneous, page 50</u></div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z323e088d895e4eb3ba7a75afe5062809" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 5.45pt;"><br>
          </td>
          <td style="width: 35.35pt; vertical-align: top; font-weight: bold;">4.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">We note your disclosure that &#8220;[t]he Offer is not being made to, nor will tenders be accepted from or on behalf of, holders of Shares in any U.S. or foreign jurisdiction in which the making of the Offer or
              acceptance thereof would not be in compliance with the laws of such jurisdiction.&#8221; While offer materials need not be disseminated into jurisdictions where it is impermissible to do so, please remove the implication that tendered shares will
              not be accepted from all stockholders. Refer to Rule 14d-10 and Section II.G.1 of Securities Exchange Act Release No. 58597 (September 19, 2008).</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 40.8pt;"><u>Response</u>: Parent and Purchaser respectfully acknowledge the Staff&#8217;s comment and advise the Staff that the TO Amendment sets forth revised disclosure on page 50 of the Offer to Purchase and
      in Exhibits (a)(1)(ii), (a)(1)(iv) and (a)(1)(v) to the Schedule TO in response to the Staff&#8217;s comment.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">***</div>
    <div><br>
    </div>
    <div style="text-align: justify;">We appreciate the time and attention the Staff has dedicated to this matter. If you have any questions regarding the response in this letter, please do not hesitate to contact me at 609-439-6256.</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="ze5faed3dc00d4e1d9b16aed7958d7078" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-align: justify;">Sincerely,</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top; border-bottom: 2px solid black;">
            <div style="text-align: justify;">/s/ Kimberly Jablonski</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-align: justify;">Kimberly Jablonski</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-align: justify;">Corporate Secretary</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: justify;">cc: Sandra Leung, Executive Vice President &amp; General Counsel, Bristol-Myers Squibb Company</div>
    <div style="text-align: justify; text-indent: 14pt;">Catherine J. Dargan, Esq., Covington &amp; Burling LLP</div>
    <div style="text-align: justify; text-indent: 14pt;">Michael J. Riella, Esq., Covington &amp; Burling LLP</div>
    <div style="text-align: justify; text-indent: 14pt;">Kerry S. Burke, Esq., Covington &amp; Burling LLP</div>
    <div style="text-align: justify; text-indent: 14pt;">Kyle Rabe, Esq., Covington &amp; Burling LLP
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>ny20021323x3_image01.jpg
<TEXT>
begin 644 ny20021323x3_image01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1"  I 2P# 2(  A$! Q$!_\0
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M:V_UN_?C^+H,?3F@+'3T45S'@?Q7_P )2NJ'[']E^PW36W^MW[\?Q=!CZ<T
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MLF,745Q&"?X6,C[3^!P?PKB-'U&3Q5H_A#P;-N\VWO7%\AZB*'D ^VTD?5:
M.HO=>\26FB>%/#MG=LWB/6(_.FNYP&,*'YNF.H&1T_A/<YHUZ7Q+\.YM/U6\
M\03:WI,LX@NX9X@I7()W+R?0_B!US3?B?9+/\4_"@N+R[T^WN(7MUNK67RI%
M?+8"MCC)=1]#5GQCX.\/V&GPCQ3XN\4/:S2A(XY[LSAWP<801D_CC^= $GQ%
MU_7=/^(&@V.@2F0W5LX6W8_NW<[PK-[#AC[+2^)M0\2^!O UY=ZAJR:GJEU<
M)%%-Y05+;<#G Z'&#CCJ1QVH\3((_C7X-1<D+:2J">O"R5V'CJ30%T!X?%;Q
MIIUPXBRX;[_)&".0>"<^U '&WOAGQII>FIJ>D>*[K5=03:[6DJ@PS XR%R<8
M_+VQ7I>G337&GVTUU ;>XDC5I(2<F-B.5R.N#Q7E6O\ AK6? 6ASZIX6\2W1
ML;0!S8WH$B%<CA3T'7H ,^N:]*\,ZI_;7A[3M2,?EM=0)*R?W21R![9IB9Y+
M;:I<_#+QOX@EUG3KB;1]7N#/'=PKNQ\S,!Z'[Y!!(/&1UKN;&\\'_$&YLKN&
M1+R\TYO.A4N\4D+9!SMR,C*CU'%7_#OBO3/$U_JNF10SQW%@YBG@ND4;N2"0
M 3D9'ZCUKSOXE:1IWAKQEX6O_#D45GJ<]V%>WM_E$B[E&=HX&<E3CKFD/<VO
M$&J:]XE^($_ACP_J)TJRL(1+=W2)N=F(!P/^^@,<=">>!65KMUXK\,^+?"FD
MW>N27MA=WJ 7&P(\BET#1OUSC/!Z_,:TO";K:?&[Q7;3G9+<01R1 \;P A./
M7K^A]*;\6;J%O'?@&U5P9UOUE90>54R1@'\2#^5 >1J:#K&H3_&/Q'I<UU(^
MGV]I&\4!/RHQ6+)'_?1_.CQMJ]_9?$/P?96EU)%:7;R">)3Q)C&,UG>'G6/X
M^^)T<A6DL8R@/\6$ASC_ #VIOQ GC;XM^"(%8&6,L[+GD!CQ_P"@F@.IIZ+J
M]_-\9=?TN6ZD;3X+*.2* GY48B+)'_?1_.N-^&VFZUK%UXFM;#57TG3TU!WD
MF@0&65R2 H)^Z !D]^171^'_ /DOGB?_ +!\?_H,-1? ^YB-UXLM=X\]=1:4
MKGG:21G\Q0!=\):MK.C^/+CPGX@OCJ,<EO\ :;*Z= KD?W6Q]&_[Y]^.4^&N
MF:UK%SXEMK#5GTG3TU!WDF@0&65R3A03]T #)[\BN@OW6]_:"TT6Q#_8M-83
M[>=A/F=?^_B_G3?@=<Q&X\5VH<>>NHM*5SSM)(S^8- %CPSJ&JV'C6[\'>)K
MS^U();?[39W+KM<@'H<=^#SU!7KZ>A06%K"A5(@V3DM(2[$^Y;)->;WTBWO[
M06G"V._[#IK+/CG83YG7_OXOYUZE3$SR#QUH^I^$/%3>+_#\?FVLA+7<7)"D
M_>W ?PMUSV/X5W_@SQ59>+--:ZL5EC:-@DL4@Y1L9Z]"/?\ E6]+_JW^AK@?
M@Y_R"=8_[",O\A7;*:K4&Y+WHV5_+S/0E46(PSE->]"ROY>9Z!1117$><8'C
M7PK8^+]*BL-2EN8H8YA.#;LJMN"LO<'C#&N7/PAT60C[5JFNW4?_ #SFNU*G
M\E%>CT4#NS#@\*Z3:^&KK0K"W^R6%S$\4GDGYSN7:6W'.6QW.:M>'-'M] T2
MUTNS>5[>V4JC2D%CDD\D #OZ5I44",'1_"UCI6N:OJL$EQ)/JA!G25E*#&?N
M@ 'OW)KFI/A7I\;7"Z7K.N:99W#%I+2UNML1S[8_GFO0Z*!W,;POX:TWPSI
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MI7G?PGL+;4?''BSQ+:Q@6K7+V]LPY#$MN=A]<*?^!&O6)/\ 5M]#7-?#S_D
M'_KLW\A0,N^+/#.F>*=-^Q:M$S(K;HY$;:\;>JG_ !R*Y_0_AGI&G:G!J%Y=
M:AJMU;G,)OIMZQD="!@=/?-=U10%S"U#PQ97WBK3=?FEN!>6$;1Q(K*(R&#
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!V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
